Table 1 The baseline characteristics of all the included studies
Study | Study type | Research year range | N | Age (mean range or s) | Gender (M/F) | Tumor size (mm) | Treatment total dose | Median follow-up (months) |
|---|---|---|---|---|---|---|---|---|
Eric Tran 2012 [37] | Retrospective study | 1995– 2007 | 59 | 59 (34–86) | (39/20) | 11. 4 (6.8–17) | 32%:54 CGE, 68%: 60 CGE | 63 (4–131) |
Kim TW 2018 [33] | Retrospective study | 2009– 2015 | 24 | 62 (44–85) | (14/10) | 11 (4.4–16) | 60–70 CGE | 36.5 (9–82) |
Papakostas TD 2017 [35] | Retrospective study | 1985.01– 1997.12 | 336 | 61 (24–90) | (186/150) | 18 (9.0–24.0) | 70 Gy | 84 (2. 8– 286.8) |
Bensoussan E 2016 [36] | Retrospective study | 1991.06– 2015.06 | 492 | Average: 62. 4 (19–89) | (258/234) | Average: 14. 91 (7–24.1) | 60 Gy | Average: 61.9 |
Fuss M 2001 [38] | Retrospective study | 1990.10– 1998.11 | 78 | 61(26–89) | (44/34) | 10 | 70. 2 CGE (median dose) | 34 (6–102) |
Carlo Mosci 2012 [34] | Retrospective study | 1996.08– 2007.07 | 70 | Average: 62.7 (48.6–76.8) | (43/27) | Average: 15.2 (12. 5–17.9) | 60 Gy | 52.9 (14.6–107.6) |